Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7419045
Reference Type
Journal Article
Title
Current and future perspectives of liquid biopsies in genomics-driven oncology
Author(s)
Heitzer, E; Haque, IS; Roberts, CES; Speicher, MR; ,
Year
2019
Is Peer Reviewed?
1
Journal
Nature Reviews. Genetics
ISSN:
1471-0056
EISSN:
1471-0064
Publisher
NATURE PUBLISHING GROUP
Location
LONDON
Page Numbers
71-88
Language
English
PMID
30410101
DOI
10.1038/s41576-018-0071-5
Web of Science Id
WOS:000456163700006
URL
http://www.nature.com/articles/s41576-018-0071-5
Exit
Abstract
Precision oncology seeks to leverage molecular information about cancer to improve patient outcomes. Tissue biopsy samples are widely used to characterize tumours but are limited by constraints on sampling frequency and their incomplete representation of the entire tumour bulk. Now, attention is turning to minimally invasive liquid biopsies, which enable analysis of tumour components (including circulating tumour cells and circulating tumour DNA) in bodily fluids such as blood. The potential of liquid biopsies is highlighted by studies that show they can track the evolutionary dynamics and heterogeneity of tumours and can detect very early emergence of therapy resistance, residual disease and recurrence. However, the analytical validity and clinical utility of liquid biopsies must be rigorously demonstrated before this potential can be realized.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity